Floatz logo

IMIFOPLATIN

PT-112

Promontory Therapeutics Inc.Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the PT-112 cohort.

Asset / SponsorPhaseRating
pt-112
Promontory Therapeutics Inc.
Phase 2CCC

Same molecule, other indications

IMIFOPLATIN is also rated in:

urinary system neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
CRPCDormant
CCC
Indicative ·
53 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →